Intra-Cellular Therapies Inc reports results for the quarter ended in March - Earnings Summary

Intra-Cellular Therapies

04/05/2023 14:32

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 46 cents​​ per share for the quarter ended in
March. The mean expectation of thirteen analysts for the quarter
was for a loss of 61 cents per share.
    * Revenue rose 172.3% to $95.31 million from a year ago;
analysts
expected $91.98 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 46 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates 
    * Intra-Cellular Therapies Inc shares had risen by 16.8%
this
quarter and gained 19.5% so far this year.
    * The company reported a quarterly loss of $44.05 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $73.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.61          -0.46          Beat
 Dec. 31 2022      -0.59          -0.45          Beat
 Sep. 30 2022      -0.81          -0.57          Beat
 Jun. 30 2022      -0.76          -0.92          Missed